» Articles » PMID: 9712034

Termination of Peripheral Tolerance to a T Cell Epitope by Heteroclitic Antigen Analogues

Overview
Journal J Immunol
Date 1998 Aug 26
PMID 9712034
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Treating mice with an immunodominant T cell epitope from moth cytochrome c (MCC(88-103)) can induce T cell unresponsiveness under certain conditions of administration. In this report, we determined whether T cell tolerance to MCC(88-103) in adult animals can be overcome by immunization with cross-reactive analogues of the tolerizing Ag. A panel of analogues of the tolerogen were tested for their capacity to terminate the tolerant state following in vivo immunization. As analyzed by their stimulatory capacity for a representative MCC(88-103)-specific T cell clone, this panel covered a wide range of cross-reactivity, including nonantigenic, antagonistic, weakly, and strongly antigenic peptides. Interestingly, only heteroclitic analogues, as measured in vitro by their enhanced antigenicity for the T cell clone that was specific for MCC(88-103), were capable of breaking tolerance. Thus, an immune response to the cross-reactive, heteroclitic analogues of tolerized self Ags may represent a mechanism by which Ag molecular mimicry operates.

Citing Articles

Improving antigenic peptide vaccines for cancer immunotherapy using a dominant tumor-specific T cell receptor.

Buhrman J, Jordan K, Munson D, Moore B, Kappler J, Slansky J J Biol Chem. 2013; 288(46):33213-25.

PMID: 24106273 PMC: 3829168. DOI: 10.1074/jbc.M113.509554.


Manipulating antigenic ligand strength to selectively target myelin-reactive CD4+ T cells in EAE.

Sabatino Jr J, Rosenthal K, Evavold B J Neuroimmune Pharmacol. 2009; 5(2):176-88.

PMID: 19904613 PMC: 2866818. DOI: 10.1007/s11481-009-9181-3.


Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trial.

Jain N, Reuben J, Kantarjian H, Li C, Gao H, Lee B Cancer. 2009; 115(17):3924-34.

PMID: 19536894 PMC: 5534348. DOI: 10.1002/cncr.24468.


Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells.

Babatz J, Rollig C, Lobel B, Folprecht G, Haack M, Gunther H Cancer Immunol Immunother. 2005; 55(3):268-76.

PMID: 16034561 PMC: 11031026. DOI: 10.1007/s00262-005-0021-x.


Diversity and recognition efficiency of T cell responses to cancer.

Stuge T, Holmes S, Saharan S, Tuettenberg A, Roederer M, Weber J PLoS Med. 2004; 1(2):e28.

PMID: 15578105 PMC: 529423. DOI: 10.1371/journal.pmed.0010028.